380 related articles for article (PubMed ID: 10975674)
1. Transgene amplification and persistence after delivery of retroviral vector and packaging functions with E1/E4-deleted adenoviruses.
Torrent C; Jullien C; Klatzmann D; Perricaudet M; Yeh P
Cancer Gene Ther; 2000 Aug; 7(8):1135-44. PubMed ID: 10975674
[TBL] [Abstract][Full Text] [Related]
2. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
3. 'Autoreplication' of the vector genome in recombinant adenoviral vectors with different E1 region deletions and transgenes.
Marienfeld U; Haack A; Thalheimer P; Schneider-Rasp S; Brackmann HH; Poller W
Gene Ther; 1999 Jun; 6(6):1101-13. PubMed ID: 10455413
[TBL] [Abstract][Full Text] [Related]
4. Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors.
Sena-Esteves M; Hampl JA; Camp SM; Breakefield XO
J Gene Med; 2002; 4(3):229-39. PubMed ID: 12112640
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of transgenes delivered by recombinant adenovirus vectors through extrachromosomal replication.
Krougliak VA; Krougliak N; Eisensmith RC
J Gene Med; 2001; 3(1):51-8. PubMed ID: 11269336
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors.
Trajcevski S; Solly SK; Frisén C; Trenado A; Cosset FL; Klatzmann D
J Gene Med; 2005 Mar; 7(3):276-87. PubMed ID: 15515136
[TBL] [Abstract][Full Text] [Related]
8. Construction of new retroviral producer cells from adenoviral and retroviral vectors.
Lin X
Gene Ther; 1998 Sep; 5(9):1251-8. PubMed ID: 9930327
[TBL] [Abstract][Full Text] [Related]
9. Construction of retroviral vectors with enhanced efficiency of transgene expression.
Hahm SH; Yi Y; Lee DK; Noh MJ; Yun L; Hwang S; Lee KH
J Virol Methods; 2004 Nov; 121(2):127-36. PubMed ID: 15381349
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system.
Chang LJ; Urlacher V; Iwakuma T; Cui Y; Zucali J
Gene Ther; 1999 May; 6(5):715-28. PubMed ID: 10505094
[TBL] [Abstract][Full Text] [Related]
11. A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes.
Weijtens ME; Willemsen RA; Hart EH; Bolhuis RL
Gene Ther; 1998 Sep; 5(9):1195-203. PubMed ID: 9930320
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus vectors as transcomplementing templates for the production of replication defective retroviral vectors.
Ramsey WJ; Caplen NJ; Li Q; Higginbotham JN; Shah M; Blaese RM
Biochem Biophys Res Commun; 1998 May; 246(3):912-9. PubMed ID: 9618311
[TBL] [Abstract][Full Text] [Related]
13. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Van Linthout S; Lusky M; Collen D; De Geest B
Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
[TBL] [Abstract][Full Text] [Related]
14. Adeno-retroviral chimeric viruses as in vivo transducing agents.
Caplen NJ; Higginbotham JN; Scheel JR; Vahanian N; Yoshida Y; Hamada H; Blaese RM; Ramsey WJ
Gene Ther; 1999 Mar; 6(3):454-9. PubMed ID: 10435096
[TBL] [Abstract][Full Text] [Related]
15. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
16. Development of a recombinant adenovirus vector production system free of replication-competent adenovirus by utilizing a packaging size limit of the viral genome.
Suzuki T; Sasaki T; Yano K; Sakurai F; Kawabata K; Kondoh M; Hayakawa T; Yagi K; Mizuguchi H
Virus Res; 2011 Jun; 158(1-2):154-60. PubMed ID: 21470569
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of adenoviral/retroviral chimeric vectors and their use for efficient screening of retroviral producer cell lines.
Duisit G; Salvetti A; Moullier P; Cosset FL
Hum Gene Ther; 1999 Jan; 10(2):189-200. PubMed ID: 10022544
[TBL] [Abstract][Full Text] [Related]
18. Effect of posttranscriptional regulatory elements on transgene expression and virus production in the context of retrovirus vectors.
Hlavaty J; Schittmayer M; Stracke A; Jandl G; Knapp E; Felber BK; Salmons B; Günzburg WH; Renner M
Virology; 2005 Oct; 341(1):1-11. PubMed ID: 16054668
[TBL] [Abstract][Full Text] [Related]
19. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses.
Kuate S; Stefanou D; Hoffmann D; Wildner O; Uberla K
J Gene Med; 2004 Nov; 6(11):1197-205. PubMed ID: 15459964
[TBL] [Abstract][Full Text] [Related]
20. Strain-specific rate of shutdown of CMV enhancer activity in murine liver confirmed by use of persistent [E1(-), E2b(-)] adenoviral vectors.
Everett RS; Evans HK; Hodges BL; Ding EY; Serra DM; Amalfitano A
Virology; 2004 Jul; 325(1):96-105. PubMed ID: 15231389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]